Protalix BioTherapeutics, Inc. Debt Conversion, Converted Instrument, Amount
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2026-03-18
- Protalix BioTherapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2023-12-31 was $0.00.
- Protalix BioTherapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2023-09-30 was $0.00.
- Protalix BioTherapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2018-12-31 was $49.00K, a 99.43% decline year-over-year.
- Protalix BioTherapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2018-09-30 was $99.00K, a 97.62% decline year-over-year.
- Protalix BioTherapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2025 was $0.00.
- Protalix BioTherapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Protalix BioTherapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2023 was $7.78M.
- Protalix BioTherapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-18 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-03-17 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $7.78M 10-K · filed 2026-03-18 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $7.78M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $7.78M 10-Q · filed 2024-08-14 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 | |||
| 2018-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $148.00K derived: sum of 2 quarters · filed 2021-03-30 | $1.30M derived: sum of 3 quarters · filed 2021-03-30 | $2.29M 10-K · filed 2021-03-30 |
| 2018-09-30 | $99.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.25M derived: sum of 2 quarters · filed 2019-11-07 | $2.24M 10-Q · filed 2019-11-07 | $10.83M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $2.14M 10-Q · filed 2019-08-08 | $10.73M derived: sum of 3 quarters · filed 2020-03-12 | $14.90M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $987.00K 10-Q · filed 2019-05-06 | $9.58M derived: sum of 2 quarters · filed 2020-03-12 | $13.75M derived: sum of 3 quarters · filed 2020-03-12 | $16.73M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $12.76M derived: sum of 2 quarters · filed 2020-03-12 | $15.75M derived: sum of 3 quarters · filed 2020-03-12 | $16.26M 10-K · filed 2020-03-12 |
| 2017-09-30 | $4.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-03-18 | $7.15M derived: sum of 2 quarters · filed 2019-03-18 | $7.67M 10-Q · filed 2019-03-18 | |
| 2017-06-30 | $2.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-03-18 | $3.50M 10-Q · filed 2019-03-18 | ||
| 2017-03-31 | $517.00K 10-Q · filed 2019-03-18 | |||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-08 |